|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM91 |
Gene summary for TMEM91 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM91 | Gene ID | 641649 |
| Gene name | transmembrane protein 91 | |
| Gene Alias | DSPC3 | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0002244 | UniProtAcc | Q6ZNR0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 641649 | TMEM91 | LZE4T | Human | Esophagus | ESCC | 4.02e-04 | 1.89e-01 | 0.0811 |
| 641649 | TMEM91 | LZE24T | Human | Esophagus | ESCC | 7.03e-07 | 1.90e-01 | 0.0596 |
| 641649 | TMEM91 | LZE6T | Human | Esophagus | ESCC | 4.69e-04 | 2.78e-01 | 0.0845 |
| 641649 | TMEM91 | P2T-E | Human | Esophagus | ESCC | 1.36e-06 | 2.80e-02 | 0.1177 |
| 641649 | TMEM91 | P4T-E | Human | Esophagus | ESCC | 1.84e-07 | 2.04e-01 | 0.1323 |
| 641649 | TMEM91 | P5T-E | Human | Esophagus | ESCC | 2.37e-23 | 4.97e-01 | 0.1327 |
| 641649 | TMEM91 | P8T-E | Human | Esophagus | ESCC | 8.58e-09 | 1.28e-01 | 0.0889 |
| 641649 | TMEM91 | P9T-E | Human | Esophagus | ESCC | 2.28e-09 | 1.20e-01 | 0.1131 |
| 641649 | TMEM91 | P10T-E | Human | Esophagus | ESCC | 1.92e-04 | 6.74e-02 | 0.116 |
| 641649 | TMEM91 | P11T-E | Human | Esophagus | ESCC | 4.71e-07 | 3.66e-01 | 0.1426 |
| 641649 | TMEM91 | P12T-E | Human | Esophagus | ESCC | 1.74e-16 | 2.56e-01 | 0.1122 |
| 641649 | TMEM91 | P15T-E | Human | Esophagus | ESCC | 1.06e-06 | 1.52e-01 | 0.1149 |
| 641649 | TMEM91 | P16T-E | Human | Esophagus | ESCC | 1.05e-10 | 6.94e-02 | 0.1153 |
| 641649 | TMEM91 | P20T-E | Human | Esophagus | ESCC | 2.00e-11 | 3.39e-01 | 0.1124 |
| 641649 | TMEM91 | P21T-E | Human | Esophagus | ESCC | 7.01e-03 | 4.11e-02 | 0.1617 |
| 641649 | TMEM91 | P22T-E | Human | Esophagus | ESCC | 1.11e-08 | 1.52e-01 | 0.1236 |
| 641649 | TMEM91 | P23T-E | Human | Esophagus | ESCC | 5.54e-03 | 2.41e-01 | 0.108 |
| 641649 | TMEM91 | P24T-E | Human | Esophagus | ESCC | 9.62e-06 | 1.26e-02 | 0.1287 |
| 641649 | TMEM91 | P26T-E | Human | Esophagus | ESCC | 4.43e-03 | 1.15e-01 | 0.1276 |
| 641649 | TMEM91 | P27T-E | Human | Esophagus | ESCC | 4.54e-13 | 2.64e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00022446 | Esophagus | ESCC | hematopoietic progenitor cell differentiation | 66/8552 | 114/18723 | 5.74e-03 | 2.13e-02 | 66 |
| GO:00022445 | Oral cavity | OSCC | hematopoietic progenitor cell differentiation | 57/7305 | 114/18723 | 1.09e-02 | 3.71e-02 | 57 |
| GO:00022448 | Thyroid | ATC | hematopoietic progenitor cell differentiation | 51/6293 | 114/18723 | 8.62e-03 | 3.28e-02 | 51 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM91 | SNV | Missense_Mutation | novel | c.479N>C | p.Val160Ala | p.V160A | Q6ZNR0 | protein_coding | tolerated(0.07) | benign(0.039) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TMEM91 | SNV | Missense_Mutation | c.8N>A | p.Ser3Asn | p.S3N | Q6ZNR0 | protein_coding | tolerated_low_confidence(0.42) | benign(0) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| TMEM91 | SNV | Missense_Mutation | rs368417249 | c.461N>T | p.Thr154Met | p.T154M | Q6ZNR0 | protein_coding | tolerated(0.26) | benign(0.056) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM91 | SNV | Missense_Mutation | c.34N>T | p.Pro12Ser | p.P12S | Q6ZNR0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-CA-6715-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
| TMEM91 | SNV | Missense_Mutation | c.22N>C | p.Glu8Gln | p.E8Q | Q6ZNR0 | protein_coding | deleterious_low_confidence(0) | benign(0.137) | TCGA-AG-3731-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | folinic | PR | |
| TMEM91 | SNV | Missense_Mutation | c.269N>C | p.Phe90Ser | p.F90S | Q6ZNR0 | protein_coding | deleterious(0.01) | benign(0) | TCGA-AG-3999-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Unspecific | PD | ||
| TMEM91 | SNV | Missense_Mutation | rs763314619 | c.257G>A | p.Arg86His | p.R86H | Q6ZNR0 | protein_coding | tolerated(0.46) | benign(0.001) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TMEM91 | SNV | Missense_Mutation | c.266C>A | p.Pro89Gln | p.P89Q | Q6ZNR0 | protein_coding | deleterious(0.03) | possibly_damaging(0.857) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| TMEM91 | SNV | Missense_Mutation | novel | c.416G>A | p.Arg139His | p.R139H | Q6ZNR0 | protein_coding | deleterious(0.03) | benign(0.009) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM91 | SNV | Missense_Mutation | novel | c.280N>A | p.Asp94Asn | p.D94N | Q6ZNR0 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |